[1] Tohma T,Okazumi S,Makino H,et al. Relationship between glucose transporter,hexokinase and FDG-PET in esophageal cancer. Hepatogastr oenterol,2005,52:486-490. [2] Roedl JB,Colen RR,King K,et al. Visual PET/ CT scoring for nonspecific F-18-FDG uptake in the differentiation of early malignant and benign esophageal lesions. Am J Roentgenol,2008,191:515-521. [3] Kato H,Miyazaki T,Nakajima M,et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer,2005,103:148-156. [4] Puli SR,Reddy JB,Bechtold ML,et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol,2008,14:1479-1490. [5] Kato H,Kimura H,Nakajima M,et al. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer. Oncol Rep,2008,20:857-862. [6] van Vliet EP,Heijenbrok-Kal MH,Hunink MG,et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer,2008,98:547-557. [7] Walker AJ,Spier BJ,Perlman SB,et al. Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol,2011,13:167-171. [8] Hu Q,Wang W,Zhong X,et al. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Eur J Radioi,2009,70:320-324. [9] Bar-Shalom R,Guralnik L,Tsalic M,et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging,2005,32:918-924. [10] Konski A,Doss M,Milestone B,et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma.Int J Radiat Oncol Biol Phys,2005,61:1123-1128. [11] 任瑞美,付正,于金明,等.FDG PET-CT在食管癌放疗靶区勾画中的作用.中华放射肿瘤学杂志,2009,18:429-430. [12] Muijs CT,Schreurs LM,Busz DM,et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol,2009,93:447-453. [13] Gondi V,Bradley K,Mehta M,et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys,2007,67:187-195. [14] Vali FS,Nagda S,Hall W,et al. Comparison of standardized uptake value-based positron emission tomography and computed tomography target volumes in esophageal cancer patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys,2010,78:1057-1063. [15] Mamede M,El Fakhri G,Abreue-Lima P,et al. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med,2007,21:553-562. [16] Yu W,Fu XL,Zhang YJ,et al. GTV spatial conformity between different delineation methods by 18 FDG PET/CT and pathology in esophageal cancer. Radiother Oncol,2009,93:441-446. [17] Zhong X,Yu J,Zhang B,et al. Using(18)F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys,2009,73:136-141. [18] 郭洪波,于金明,张百江,等. 氟脱氧葡萄糖PET-CT确定食管癌淋巴结放疗靶区的可行性研究.中华放射肿瘤学杂志,2007,16:10-14. [19] Yu W,Fu XL,Zhang YJ,et al. A prospective evaluation of staging and target volume definition of lymph nodes by 18FDG PET/CT in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys,2011,81:e759-765. [20] Vesprini D,Ung Y,Dinniwell R,et al. Improving observer variability in target delineation for gastro-oesophageal cancer-the role of(18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. Clin Oncol,2008,20:631-638. [21] Schreurs LM,Busz DM,Paardekooper GM,et al. Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability. Dis Esophagus,2010,23:493-501. [22] Madani I,Duthoy W,Derrie C,et al. Positron emission tomography guidedfocal dose escalation using intensity modulated radiotherapy for head andneck cancer. Int J Radiat Oncol Biol Phys,2007,68:126-135. [23] Han D,Yu J,Yu Y,et al. Comparison of(18)F-fluorothymidine and(18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys,2010,76:1235-1241. [24] 韩大力,钟小军,于金明,等. 18F-FLT和 18F-FDG PET/CT对胸段食管癌淋巴结分期诊断的对比研究.中华核医学杂志,2010,30:383-386. [25] Gwyter SJ. Current standards for response evaluation by imaging techniques. Eur J Nucl Med Mol Imaging,2006,33:11-15. [26] Brucher BL,Weber W,Bauer M,et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg,2001,233:300-309. [27] Cerfolio RJ,Bryant AS,Ohja B,et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration,integrated positron emission tomography with computed tomography,and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg,2005,129:1232-1241. [28] Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology,2010,254:707-717. [29] van Heijl M,Omloo JM,van Berge-Henegouwen MI,et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg,2011,253:56-63. [30] Ma J,Song Y,Yu J,et al. Linear correlation between patient survival and decreased percentage of tumor[18F]fluorodeoxyglucose uptake for late-course accelerated hyperfractionated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys,2011,In press. [31] Roedl JB,Colen RR,Holalkere NS,et al. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT comparison to histopathologic and clinical response evaluation. Radiother Oncol,2009,89:278-286. [32] Seung HH,Joon YC,Young MS,et al. Prognostic value of metabolic tumor volume measured by 18F-Fluorodeox-yglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol,2010,17:115-122. [33] Hatt M,Visvikis D,Albarghach N,et al. Prognostic value of 18 F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging,2011,38:1191-1202.
2012, Vol. 21 
